Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

ment for hepatitis C patients with unmet needs, including patients co-infected with HIV and HCV, African Americans, patients with cirrhosis, and patients who have failed to respond to previous therapy.

Important Safety Information about PEGASYS

PEGASYS, alone or in combination with COPEGUS, is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A).

Alpha interferons, including PEGASYS(R) (Peginterferon alfa-2a), may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping PEGASYS therapy (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

Use with Ribavirin. Ribavirin, including COPEGUS(R), may cause birth defects and/or death of the fetus. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin causes hemolytic anemia. The anemia associated with ribavirin therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a potential carcinogen (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

PEGASYS is contraindicated in patients with hypersensitivity to PEGASYS or any of its components, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6; class B and C) in cirrhotic CHC monoinfected patients before or during tre
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... Calif. , May 1, 2015  AcelRx Pharmaceuticals, Inc. ... on the development and commercialization of innovative therapies for ... that Timothy E. Morris , chief financial officer ... of the events are as follows: Mizuho ... 5 Location:  The Omni Berkshire Place, New ...
(Date:4/30/2015)... April 30, 2015 Omnicell, Inc. (NASDAQ: OMCL ... solutions to healthcare systems, today announced results for its ... results: Revenue for the first quarter of 2015 was ... first quarter of 2014, and down $5.3 million or ... First quarter 2015 net income as reported in accordance ...
(Date:4/30/2015)... , April 30, 2015   Regulus Therapeutics Inc ... the discovery and development of innovative medicines targeting microRNAs, ... highlights for the quarter ended March 31, 2015 on ... close. Regulus will host a conference ... 5:00 pm Eastern Daylight Time to discuss its first ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3
... Eli Lilly and Company (NYSE: LLY ) ... chairman, president, and chief executive officer about his meeting ... economic growth, job creation, American innovation and competiveness: ... biopharmaceutical industry and take part in this very important ...
... NEW BRUNSWICK, N.J., Dec. 15, 2010 Johnson & ... Alex Gorsky, currently Worldwide Chairman, Medical Devices & Diagnostics ... been appointed Vice Chairmen of the Executive Committee and ... Chief Executive Officer, in an expanded Office of the ...
Cached Medicine Technology:Lilly Statement Regarding President Obama's Meeting With U.S. Business Leaders 2Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee 2Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee 3
(Date:5/3/2015)... 03, 2015 “ BolehVPN ” was featured ... features the latest and coolest technology products available to consumers. ... conducted the review and shared with viewers how to protect ... these days is on computers and even more so online. ... meet people all over the world. In terms of work, ...
(Date:5/3/2015)... It is not too late to register to take ... of Lissa Anne Been in Arnold, Missouri on May 9, ... to honor her loving memory. It has benefited the renowned Brain ... turned 37, Lissa suffered a brain aneurysm . After two ... This event is designed to serve as a remembrance of her ...
(Date:5/2/2015)... 2015 Vancouver fencing company, QS Fencing, has ... advice to prospective clients related to their questions on railings ... railings around their decks and patios. While that seems like ... up once the person rolls up their sleeve to start ... railing in finding a gate that matches it. , Instead ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 We are ... The Delray Recovery Center as one of the Top ... known in the addiction treatment field for their ethics ... to innovate and to continue their educational efforts. The ... workplace environment, never forgetting their purpose – to help ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 As ... laxity issues of the face, neck and décolleté, ... concept with real potential for the success of ... the ThermiHealth Clinical Advisory Council, ThermiGyn’s Women’s Health ... FACS, ACGE, concluded that ThermiGyn’s temperature controlled radio ...
Breaking Medicine News(10 mins):Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3
... Georgia Tech researchers to decode exactly how a cell ... and reacts //to a broad spectrum of complex biomolecules ... that are capable of targeting some of the most ... used for studying cell communications suffer from significant deficiencies. ...
... by which environmental stimulation decelerates Alzheimer's disease, further ... neurological decline. ,A paper to this effect ... of amyloid angiopathy and A? plaque burden after ... pathways," appears in the2006 August issue of The ...
... August 1 at the annual meeting of the American ... a specific mixture// of electron and x-ray beams that ... of collateral damage in breast cancer patients. Jinsheng Li, ... Cancer Center in Philadelphia developed this specific mixture using ...
... of Cincinnati on skin cancers has revealed that people with ... when they do get //it they are associated with higher ... done at an advanced stage. ,In a ... Hugh Gloster, Dermatologist at University of Cincinnati, he has concluded ...
... York City has discovered that chronic pain occurs as a ... were studying chronic pain at the molecular and cellular level. ... the neurons becomes excited and begin to send signals to ... stimulus is removed the nerves become dormant and there is ...
... patient was discharged for a week after undergoing successful surgery, ... Guoxing, 30, who had not seen his wife and two ... returned home Friday for a week-long visit to his family ... his face is alive and Li has been doing well, ...
Cached Medicine News:Health News:Cell Behavior Better Understood with Nano Probe 2Health News:Cell Behavior Better Understood with Nano Probe 3Health News:Active Life Decelerates Alzheimer's 2Health News:Radiation Cocktail May Reduce Risk of Damage To Other Organs In Breast Cancer 2
Townsend is a endocervical stainless-steel curette with round tapered tip....
Available in 5, 8 and 12 mm bite, with and without teeth....
...
...
Medicine Products: